These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 8883963)
1. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Alonso DF; Farías EF; Ladeda V; Davel L; Puricelli L; Bal de Kier Joffé E Breast Cancer Res Treat; 1996; 40(3):209-23. PubMed ID: 8883963 [TBL] [Abstract][Full Text] [Related]
2. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma. Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Alonso DF; Tejera AM; Farias EF; Bal de Kier Joffe E; Gomez DE Anticancer Res; 1998; 18(6A):4499-504. PubMed ID: 9891516 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Towle MJ; Lee A; Maduakor EC; Schwartz CE; Bridges AJ; Littlefield BA Cancer Res; 1993 Jun; 53(11):2553-9. PubMed ID: 8495419 [TBL] [Abstract][Full Text] [Related]
5. Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer. Evans DM; Sloan-Stakleff KD Invasion Metastasis; 1998-1999; 18(5-6):252-60. PubMed ID: 10729770 [TBL] [Abstract][Full Text] [Related]
6. Suppression of the invasive capacity of human breast cancer cells by inhibition of urokinase plasminogen activator via amiloride and B428. Evans DM; Sloan-Stakleff K Am Surg; 2000 May; 66(5):460-4. PubMed ID: 10824746 [TBL] [Abstract][Full Text] [Related]
8. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700 [TBL] [Abstract][Full Text] [Related]
9. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Guo Y; Mazar AP; Lebrun JJ; Rabbani SA Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425 [TBL] [Abstract][Full Text] [Related]
10. Characterization of F3II, a sarcomatoid mammary carcinoma cell line originated from a clonal subpopulation of a mouse adenocarcinoma. Alonso DF; Farías EF; Urtreger A; Ladeda V; Vidal MC; Bal De Kier Joffé E J Surg Oncol; 1996 Aug; 62(4):288-97. PubMed ID: 8691844 [TBL] [Abstract][Full Text] [Related]
11. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Xing RH; Mazar A; Henkin J; Rabbani SA Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032 [TBL] [Abstract][Full Text] [Related]
12. Modulation of urokinase-type plasminogen activator and metalloproteinase activities in cultured mouse mammary-carcinoma cells: enhancement by paclitaxel and inhibition by nocodazole. Alonso DF; Farina HG; Arregui C; Aon MA; Gomez DE Int J Cancer; 1999 Oct; 83(2):242-6. PubMed ID: 10471534 [TBL] [Abstract][Full Text] [Related]
13. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer. Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401 [TBL] [Abstract][Full Text] [Related]
14. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87). Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model. Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966 [TBL] [Abstract][Full Text] [Related]
16. Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Evans DM; Sloan Stakleff KD Clin Exp Metastasis; 2004; 21(4):339-46. PubMed ID: 15554390 [TBL] [Abstract][Full Text] [Related]
17. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945 [TBL] [Abstract][Full Text] [Related]
18. Varying patterns of expression of insulin-like growth factors I and II and their receptors in murine mammary adenocarcinomas of different metastasizing ability. Guerra FK; Eijan AM; Puricelli L; Alonso DF; Bal de Kier Joffé E; Kornblihgtt AR; Charreau EH; Elizalde PV Int J Cancer; 1996 Mar; 65(6):812-20. PubMed ID: 8631597 [TBL] [Abstract][Full Text] [Related]
19. Verapamil inhibits tumor protease production, local invasion and metastasis development in murine carcinoma cells. Farías EF; Aguirre Ghiso JA; Ladeda V; Bal de Kier Joffé E Int J Cancer; 1998 Dec; 78(6):727-34. PubMed ID: 9833766 [TBL] [Abstract][Full Text] [Related]
20. Antimetastatic activity of insulin-like growth factor binding protein-3 in lung cancer is mediated by insulin-like growth factor-independent urokinase-type plasminogen activator inhibition. Oh SH; Lee OH; Schroeder CP; Oh YW; Ke S; Cha HJ; Park RW; Onn A; Herbst RS; Li C; Lee HY Mol Cancer Ther; 2006 Nov; 5(11):2685-95. PubMed ID: 17121915 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]